ARS Pharmaceuticals Forecasts 180.8% EPS Drop and 70.3% Revenue Decline
ARS Pharmaceuticals, Inc. is expected to post a $0.42 loss per share on $25.74 million revenue in Q4 2025, a 180.8% year-over-year EPS decline and a 70.3% revenue drop. Its Earnings ESP of +39.90% and a #3 analyst ranking suggest a likely EPS beat when it reports results on March 9.
1. Upcoming Q4 Results
ARS Pharmaceuticals, Inc. will release Q4 2025 results on March 9, with analysts forecasting a $0.42 per share loss on $25.74 million of revenue.
2. Consensus Estimate Details
Current estimates imply a 180.8% year-over-year decline in EPS and a 70.3% drop in revenue, highlighting significant sales pressure from reduced product volumes.
3. Analyst Optimism and Implications
An Earnings ESP of +39.90% combined with a #3 analyst ranking indicates growing analyst optimism and raises the probability of an EPS beat, which could trigger short-term stock appreciation.